Meme infiltratif duktal karsinomlarında histopatolojik grade ve proliferasyon belirleyicilerinin prognostik amaçlı kullanımı

Amaç: Çalışmamızda meme kanserlerinde prognozu belirlemede kullanılan proliferasyon markerlarının tümörün histopaiolojik grade'i ve aksiller tutulumla bağlantısını araştırmayı amaçladık. Yöntem: Yaşları 35-76 arasında değişen 39 kadın hastadan alınan örnekler Selçuk Üniversitesi Meram Tıp Fakültesi Patoloji Anabilim Dalında incelendi. Arşivlenmiş bloklardan alınan kesitler immunohistokimyasal olarak c-erb-B2, p53, Ki-67, PCNA, östrojen ve progesteron ile boyandı. Hematoksilen- eosin boyamada tümörler Elston-Ellis modifikasyonuna sahip Scarff-Bloom-Richardson yöntemi (Nottingham) kullanılarak grade'lendi. Bulgular: Ki-67 ile c-erb-B2; p53 ile tümör grade'i; PCNA ile östrojen; progesteron ile östrojen ve PCNA ile progesteron arasında anlamlı ilişki olduğu sonucuna varıldı. Sonuç: c-erb-B2, p53, Ki-67, PCNA, östrojen ve progesteron meme kanseri grade'lemesinde önemli markerlardır.

Using of proliferation markers and histopathologic grade in infiltrative ductal carcinoma as a prognostic marker

Objective: The aim of this study was to explain prognostically importance of celi proliferation markers and histopathologic grade in infiltrative ductal carcinoma. Methods: Therefore 39 specimens excised from vvomen aged 35-76 and had diagnosed as infiltrative ductal carcinoma by Department of Pathology of Selçuk University, Meram Medical Faculty. The slides prepared from archived paraffin blocks were stained immunohistochemistry with estrogen protein receptor, progesterone protein receptor, Ki-67, PCNA, p53 and c-erb-B2. Grade of the tümör was determined with Nottigham system. Results: it is concluded that there are statistically significant relationships betvveen some proliferation markers and grade of the tumor. Conclusion: c-erb-B2, p53, Ki-67, PCNA, estrogen and progesterone are important markers in the grading of breast cancer.

Kaynakça

1. Rosai J: Breast. In: Ackerman’s Surgical Pathology. 1996, 8. ed. Vol: 2. Chapter: 20, 1623-6.

2. Clayton F. Pathological correlates of prognosis in lymph node-negative infiltrating ductal carcinomas: Mitotic count is the best single indicator. Cancer 1991;68:1309-17.

3. Aranda I F, Laforga B J. Cellular proliferation in breast ductal infiltrating carcinoma. Pathol Res Pract 1997;193:683-8.

4. Donhuijsen K, Schmidt U, Hirche H. Changes in mitotic rate and cycle fractions caused by delayed fixation. Hum Pathol 1990;21:709-14.

5. Verhoeven D, Bourgeois N, Derde MP. Comparison of cell growth in different parts of breast cancers. Histopathology 1990;17:505-9.

6. Jensen R A, Page DL, Dupont WD, Rogers LW: Benign disorders and disease of the breast. 1989, Biliere Tindall, London.

7. Bottini A, Berruti A, Bersiga A, Brizi MP, Bruzzi P, Aguggini S. Relationship between tumour shrinkage and reduction Ki-67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001;19:1106-12.

8. Shoker BS, Jarvis C, Clarke RB, Anderson E, Munro C, Davies MP. Abnormal regulation of the estrojen reseptor in benign breast lesions. J Clin Pathol 2000; 53:778-83.

9. Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M. Cell biological factors in ductal cacinoma in situ (DCIS) of the breast- relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001;37:1514-22.

10. Horita K, Yamaguchi A, Hirose K, Ishida M, Noriki S, Imamura Y, et al. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 2001;45:73-84.

11. Aziz SA, Pervez S, Khan S, Kayani N, Azam SI, Rahbar MH. Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: A unique clinical experience. Breast J 2001;7:398-404.

12. Jarvinen TA, Tanner M, Rantanen V, Barlund M, Borg A, Greinman S. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-47.

13. Bezwoda WR. C-erb-B2 expression to treatment in metastatic breast cancer. Med Oncol. 2000;17:22-8.

14. Soslow RA, Carlson DL, Horenstein MG, Osborne MP. A comparison of cell cycle markers in well differentiated lobular and ductal carcinomas. Breast Cancer Res Treat 2000;61:161-70.

15. Birner P, Oberhuber G, Stani J. Evaluation of the United States food and drug administration- approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7:2001:669-75.

16. Fitzgibbons ER, Page DL, Weaver D, Thor AD, Allred DC, Clark GM. Prognostic factors in breast cancer. College of American Pathologists Concensus Statement 1999. Arch Pathol Lab Med 124:2000:66-78.

17. Silva JM, Gonzales R, Provencio M, Dominguez G, Garcia JM, Gallego I, et al. Loss of heterozygosity in BRCA1 and BRCA2 markers and high grade malignancy in breast cancer. Breast Cancer Res Treat 1999;53:9-17.

18. Dutta A, Chandra R, Leiter LM, Lester S. Cyclins as markers of tumour proliferation: Immunohistochemical studies in breast cancers. Proc Natl Acad Sci 1995;92:5386-90.

19. Kato T, Kimura T, Takami N, Miyakawa R, Tanaka S. New prognostic factors associated with long-term survival in node- negative breast cancer patients. Breast Cancer 1999; 6:370-7.

20. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. British J Cancer 2001:85,869-74.

21. Amat S, Penault-Llorca F, Cure H. Scarff- Bloom- Richardson (SBR) grading: A pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy. Int J Oncology 2002;20: 791-6,.

22. Raabe N, Schistad O, Sauer T, Bofin A. Prognosis of radically operated breast carcinoma patients. APMIS 1997;105:363-70.

23. Tuczek HV, Fritz P, Schwarzmann P. Breast carcinoma: Correlations between visual diagnostic criteria for histologic grading and features of image analysis. Analyt Quant Cytol Histol 1996;18:481-93.

24. Smith B F, Zappi E M. Relationships between image cytometric DNA index, proliferation fraction and multipoidy and conventional nuclear grade in breast carcinoma. Modern Pathology 1993;6:606-11.

Kaynak Göster